Pharmacovigilance Associate
ROLE DEFINITION & RESPONSIBILITIES
A Pharmacovigilance (PV) Associate monitors, evaluates, and ensures the clinical safety of pharmaceutical drugs and biologics throughout pre-clinical trials and post-market commercialization. They protect patient welfare by collecting, triaging, analyzing, and documenting Adverse Drug Reactions (ADRs) in accordance with global regulatory mandates such as US FDA 21 CFR 312/314, EMA GVP modules, and CDSCO requirements.
SALARY INTELLIGENCE ROADMAP
LEARNING PATHWAYS
Fundamentals of Global Drug Safety & Regulations
Master FDA 21 CFR, EMA GVP Modules, ICH Guidelines (E2A, E2B, E2C), and CDSCO pharmacovigilance framework.
Safety Database Training & Case Processing
Hands-on data entry, source document verification, causality assessment, and coding in Oracle Argus Safety.
Medical Narrative Writing & Quality Review
Compose chronologically coherent, medically robust ICSR narratives that withstand strict audit inspections.
Aggregate Safety Reports & Signal Management
Develop knowledge of Periodic Safety Update Reports (PSUR/PBRER) and statistical disproportionality scoring.
CONNECTED ZANE PROED ACADEMY COURSES
VERIFIED INTERVIEW PREPARATION
> Q: What is the critical regulatory distinction between an Adverse Event (AE) and an Adverse Drug Reaction (ADR)?
An Adverse Event (AE) is any untoward medical occurrence in a patient administered a medicinal product which does not necessarily have a causal relationship with the treatment. An Adverse Drug Reaction (ADR) requires at least a reasonable possibility of a causal relationship between the medicinal product and the adverse occurrence.
> Q: What are the strict expedited reporting timelines for Serious Adverse Reactions?
Under ICH E2A guidelines, fatal or life-threatening unexpected Serious Adverse Drug Reactions (SUSARs) must be reported to health authorities no later than 7 calendar days, with follow-up within 8 days. All other serious, unexpected ADRs must be reported within 15 calendar days.
> Q: What are the four minimum criteria required for a valid Individual Case Safety Report (ICSR)?
An ICSR is considered regulatory-valid when it contains: (1) An identifiable reporter, (2) An identifiable patient, (3) At least one suspect medicinal product, and (4) At least one adverse event or reaction.